In a recent treatment trial in models of CMT1A, Scip/Oct-6 was also most prominently upregulated at baseline and was the most responsive to the therapeutic intervention (Zhao et al., 2018). This evidence concerns the gene POU3F1 and Charcot-Marie-Tooth disease type 1A.